Cellebrite seen 27% undervalued despite guidance cut
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
A discounted cash flow model suggests Cellebrite (CLBT) stock may be 27% undervalued, even after a revenue guidance cut prompted investor caution. The stock has gained 44.1% over three years, and projections point to growing free cash flow. Plans for U.S. redomiciliation, Genesis AI platform investment and new leadership could lift intrinsic value.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.